Innovation Pharmaceuticals   Report issue

For profit Phase 2
Founded: Beverley MA United States (2007)

Organization Overview

First Clinical Trial
2012
NCT01664000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cellceutix Corporation | Innovation Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: Innovation Pharmaceuticals (2) Acquired (3)

abacavir (ziagen) (3 trials)

brilacidin (5 trials)

daptomycin (cubicin) (2 trials)

pmx-60056 (1 trial)

thioureidobutyronitrile (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cellulitis (Phase 2)

Communicable Diseases (Phase 2)

Head and Neck Neoplasms (Phase 2)

Infections (Phase 2)

Mucositis (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Psoriasis (Phase 2)

Skin Diseases, Infectious (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 5